Vraylar (cariprazine) leaves your body much more slowly than most psychiatric medications, which means the effects of stopping it unfold gradually over weeks rather than days. This unusually long exit window affects everything from withdrawal symptoms to relapse risk, and it’s one of the most important things to understand before discontinuing.
Why Vraylar Takes Weeks to Leave Your System
Vraylar is pharmacokinetically unusual among antipsychotics. The parent drug, cariprazine, has a half-life of roughly 3 to 6 days. But your body converts it into active metabolites that keep working long after you swallow your last pill. The most important one, called DDCAR, has an estimated half-life of 2 to 3 weeks. That means it takes five weeks or longer for the drug’s total activity to fully clear.
After your last dose, the parent drug drops by about 50% within the first day. But the total active drug level in your blood, including metabolites, only drops by about 50% after one full week. This slow tapering effect is essentially a built-in gradual withdrawal that most other antipsychotics don’t provide. It’s both an advantage (smoother transition) and a complication (effects linger longer than expected).
Withdrawal Symptoms to Expect
Because Vraylar clears so slowly, withdrawal symptoms tend to be delayed and more gradual compared to shorter-acting antipsychotics. Still, discontinuation can produce a recognizable set of physical and psychological effects. Common withdrawal symptoms from antipsychotics include:
- Sleep disruption: insomnia is one of the most frequently reported issues
- Gastrointestinal problems: nausea, vomiting, diarrhea, and loss of appetite
- Physical discomfort: headaches, aching muscles, dizziness, sweating, and abnormal skin sensations
- Mood and behavioral changes: anxiety, restlessness, irritability, agitation, and social withdrawal
- Temperature sensitivity: feeling unusually hot or cold
These symptoms don’t necessarily all appear at once, and many people experience only a few of them. Because of Vraylar’s long metabolite tail, you might not notice withdrawal effects for a week or more after stopping. They can then persist for several weeks as the remaining drug slowly clears.
Relapse Risk After Stopping
For people taking Vraylar for schizophrenia, the most significant risk of stopping is symptom relapse. In clinical studies, patients who discontinued cariprazine and switched to placebo didn’t show a clear separation in relapse rates until around day 50, again reflecting how long the drug’s metabolites stay active. The median time to relapse for patients who stopped cariprazine was 296 days, meaning half of those who relapsed did so within about 10 months.
That delayed timeline can be misleading. You might feel fine for the first month or two after stopping and assume you no longer need the medication, only to experience a return of symptoms months later. This is a well-documented pattern with antipsychotic discontinuation generally, and the long half-life of Vraylar stretches it out even further.
For people using Vraylar as an add-on treatment for major depressive disorder, the stakes are also real. Research examining insurance claim data found that patients with depression who were unable to access cariprazine due to insurance rejections had hospitalization rates 61% higher for all causes and 89% higher for mental health reasons compared to those who received the medication as prescribed.
Side Effects That May Linger or Appear Late
One counterintuitive aspect of stopping Vraylar: some side effects don’t resolve immediately, and certain ones can actually emerge after discontinuation. The most concerning is tardive dyskinesia, a movement disorder involving involuntary, repetitive motions of the face, tongue, or limbs. Tardive dyskinesia can start after you stop taking the medication, not just while you’re on it. In some cases, it persists or worsens even after discontinuation.
Side effects you experienced while taking Vraylar, such as restlessness or weight changes, may take anywhere from a few days to many weeks to resolve. The DDCAR metabolite’s long half-life of 1 to 3 weeks means that drug-related effects can continue for five weeks or more after your last dose. If you’re stopping because of a bothersome side effect, it helps to know that relief won’t be immediate.
Tapering vs. Stopping Abruptly
Vraylar’s built-in slow clearance provides a kind of natural taper, which is why some prescribers are comfortable with a straightforward stop rather than a gradual dose reduction. That said, the experience varies depending on your dose, how long you’ve been taking it, and what condition it’s treating. People who have been on higher doses for longer periods generally face a bumpier transition.
If you’re on Vraylar alongside other medications, stopping it can also shift the balance of your overall treatment. For depression, where Vraylar is used as an add-on to an antidepressant, discontinuing it means relying solely on your antidepressant again. For bipolar I disorder or schizophrenia, stopping may leave you without a primary mood stabilizer or antipsychotic, which requires careful planning around alternative treatment or close monitoring.
The weeks following discontinuation are the period to pay closest attention to your mood, sleep, energy, and thinking patterns. Because relapse and withdrawal symptoms can both emerge on a delayed timeline with this particular drug, changes that show up a month or six weeks after stopping are still potentially related to discontinuation.